Our work begins to uncover the relevance of MSLN overexpression in CRC patients as well as the implications of MSLN expression levels on pivotal CRC prognostic information, including CRC tumor sidedness, CMS subtype, genetic mutation landscape, and immune response modulation. This evidence concerns the gene MSLN and colorectal carcinoma.